Research Study

Efficacy, Safety and Immunogenicity of GSK Biologicals' HZ/su Vaccine GSK1437173A in a Phase IIIb, Open-label, Long-term Follow-up Study (ZOE-LTFU) of Studies 110390/113077 (ZOSTER-006/022) and Assessment of Additional Doses in Older Adults
Principal Investigator 
Jan P. Dutz

Overview

Body Locations and Systems 
Shingles
ClinicalTrials.gov# 
NCT02723773
Status 
Recruiting
Study Start/End 
Sep 19, 2016 to May 31, 2022
Locations 
Diamond Health Care Centre, Vancouver General Hospital
Name/Title 
Kessie Xu, Research Coordinator
Phone 
604-875-4111 ext.69487
Email Address 
kessie.xu@vch.ca
Purpose of Study 

The purpose of this study is a long-term follow-up of the two studies 110390 and 113077 (ZOSTER-006/022) to assess the efficacy, safety, and immunogenicity persistence of GSK Biologicals' Herpes Zoster subunit (HZ/su) vaccine and will include an assessment of 1 or 2 additional doses in two subgroups of older adults.

Eligibility 

Visit ClinicalTrials.gov for more information. 

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.